AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35635640 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg daily until disease progression or unacceptable toxicity
Number of subjects: 12
Study 35635643 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% weight loss
Number of subjects: 75
Study 35635644 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-containing supplements (ICS)
Number of subjects: 481
Study 35635644 — intervention group
Group type: COMPARATOR
Intervention: No iodine-containing supplements (non-users)
Number of subjects: 481
Study 35635644 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using an ICS
Number of subjects: 481
Study 35635644 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt use
Number of subjects: 481
Study 35635728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium / olodaterol combination treatment
Number of subjects: 0
Study 35635746 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Anxiety Sensitivity Program for Smoking (MASP)
Number of subjects: 200
Study 35635746 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy and smartphone-based National Cancer Institute QuitGuide app
Number of subjects: 200
Study 35635989 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented Timed Up and Go Test (TUG) in cLBP group
Number of subjects: 31
Study 35635989 — intervention group
Group type: COMPARATOR
Intervention: Instrumented Timed Up and Go Test (TUG) in healthy control group
Number of subjects: 31
Study 35635989 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic parameters during TUG in cLBP group
Number of subjects: 31
Study 35635989 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of RMQD score with temporal and kinematic parameters in cLBP group
Number of subjects: 31
Study 35635989 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NPRS score with temporal and kinematic parameters in cLBP group
Number of subjects: 31
Study 35636644 — intervention group
Group type: EXPERIMENTAL
Intervention: Untargeted metabolomics using mass spectrometry
Number of subjects: 0
Study 35636644 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel approach to establish detection limits based on targeted signal extraction
Number of subjects: 0
Study 35636648 — intervention group
Group type: EXPERIMENTAL
Intervention: WX-081 (sudapyridine)
Number of subjects: 0
Study 35636648 — intervention group
Group type: COMPARATOR
Intervention: Bedaquiline
Number of subjects: 0
Study 35636689 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 4666
Study 35636783 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening programme participants with positive screening test results (false positives, colorectal polyps, or CRC)
Number of subjects: 843
Study 35636783 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed patient-reported experience measures (PREMs) if existing measures are not applicable
Number of subjects: 843
Study 35636783 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative phenomenological study based on individual interviews
Number of subjects: 843
Study 35636782 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (MMS) during pregnancy
Number of subjects: 4500
Study 35636782 — intervention group
Group type: COMPARATOR
Intervention: Standard iron-folic acid supplementation
Number of subjects: 4500
Study 35636789 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA testing using a bespoke ctDNA assay (Signatera)
Number of subjects: 1500
Study 35636789 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA dynamics
Number of subjects: 1500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Damage Control Resuscitation (DCR) delivered prehospitally
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital factors
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital and in-hospital complications
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ultrasound
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of first 24-hours blood product administration
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital blood transfusions
Number of subjects: 500
Study 35636792 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Outcome Scale Extended
Number of subjects: 500
Study 35636921 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 350 mg once weekly for 6 months
Number of subjects: 46
Study 35637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic nutritional index (PNI) combined with serum sodium level
Number of subjects: 2882
Study 35637081 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PNI and serum sodium level
Number of subjects: 2882
Study 35637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 1394
Study 35637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt care-seeking behaviour
Number of subjects: 1394
Study 35637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of care-seeking
Number of subjects: 1394
Study 35637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Visiting health centres
Number of subjects: 1394
Study 35637506 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about malaria
Number of subjects: 1394
Study 35638924 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic aortic wall area (AWA) and prevalent thoracic plaque
Number of subjects: 1513
Study 35638924 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic aortic wall area (AWA)
Number of subjects: 1513
Study 35638924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent thoracic plaque
Number of subjects: 1513
Study 35638929 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based three-dimensional texture analysis of infrapatellar fat pad (IPFP) abnormalities
Number of subjects: 690
Study 35638929 — intervention group
Group type: COMPARATOR
Intervention: Control group matched 1:1 with case participants
Number of subjects: 690
Study 35639023 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (mental disorders)
Number of subjects: 816
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (mild disease severity, level 1)
Number of subjects: 816
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (severe mental illness, level 4)
Number of subjects: 816
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (level 1)
Number of subjects: 816
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (level 4)
Number of subjects: 816
Study 35639134 — intervention group
Group type: EXPERIMENTAL
Intervention: RECOVER group (levels 2 to 4)
Number of subjects: 816
Study 35639134 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (general population without mental disorders)
Number of subjects: 816
Study 35639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous drainage (PD)
Number of subjects: 47
Study 35639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic approach (END)
Number of subjects: 47
Study 35639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal derivation (INT)
Number of subjects: 47
Study 35639137 — intervention group
Group type: EXPERIMENTAL
Intervention: Necrosectomy (NE)
Number of subjects: 47
Study 35639457 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g daily collagen peptide supplement
Number of subjects: 40
Study 35639644 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA (BNT162b2) vaccine
Number of subjects: 164
Study 35639825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 1 (n = 8)
Number of subjects: 21
Study 35639825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 2 (n = 4)
Number of subjects: 21
Study 35639825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days in cohort 3 (n = 9)
Number of subjects: 21
Study 35639825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in patients with active BMs (overall)
Number of subjects: 21
Study 35639825 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd) in patients with measurable intracranial or extracranial lesions at baseline
Number of subjects: 21
Study 35639922 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment in CARDS patients
Number of subjects: 20
Study 35639922 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 critically ill controls
Number of subjects: 20
Study 35640004 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic BM segmentation using multilabel nnU-Net algorithm
Number of subjects: 102
Study 35640004 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics analysis of 30 different BM spaces (BMS)
Number of subjects: 102
Study 35640019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with Bv40 kernel, slice thickness of 0.6 mm
Number of subjects: 20
Study 35640019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with Bv89 kernel, slice thickness of 0.2 mm
Number of subjects: 20
Study 35640019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bv64 and Bv72 kernels for delineation of coronary artery plaques
Number of subjects: 20
Study 35640019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-resolution CCTA with PCD-CT
Number of subjects: 20
Study 35640058 — intervention group
Group type: EXPERIMENTAL
Intervention: iKinnect app
Number of subjects: 0
Study 35640058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35640224 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib
Number of subjects: 31
Study 35640276 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin-containing reverse thermal gel), 6 weekly instillations
Number of subjects: 63
Study 35640276 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-102 (mitomycin-containing reverse thermal gel)
Number of subjects: 63
Study 35640431 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (0.2 mg/kg/day, titrated to a maximum of 0.7 mg/kg/day or 0.4 mg/kg/day with stiripentol)
Number of subjects: 327
Study 35640474 — intervention group
Group type: EXPERIMENTAL
Intervention: NLG207 12 mg/m2 in combination with enzalutamide
Number of subjects: 4
Study 35640561 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for >1 year
Number of subjects: 215
Study 35640561 — intervention group
Group type: COMPARATOR
Intervention: No lifestyle intervention
Number of subjects: 215
Study 35640864 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based pelvic floor physical therapy
Number of subjects: 60
Study 35640864 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeeze pressure (>192.5 mm Hg on at least 1 of 3 attempts)
Number of subjects: 60
Study 35640864 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited squeeze duration (inability to sustain 50% of squeeze pressure for >20 seconds)
Number of subjects: 60
Study 35640864 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BET with squeeze duration (BET > 6.5 seconds and limited squeeze duration)
Number of subjects: 60
Study 35640864 — intervention group
Group type: EXPERIMENTAL
Intervention: BET as a single test
Number of subjects: 60
Study 35640959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 35640959 — intervention group
Group type: EXPERIMENTAL
Intervention: FVC <70% predicted
Number of subjects: 0
Study 35640959 — intervention group
Group type: EXPERIMENTAL
Intervention: Major (>10%) improvement/worsening in FVC
Number of subjects: 0
Study 35640975 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance prophylactic cranial irradiation (HA-PCI)
Number of subjects: 103
Study 35640975 — intervention group
Group type: COMPARATOR
Intervention: Conventional prophylactic cranial irradiation (PCI)
Number of subjects: 103
Study 35641193 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 17840
Study 35641193 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater overall diet quality
Number of subjects: 17840
Study 35641193 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional eating
Number of subjects: 17840
Study 35641194 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of phylloquinone thrice weekly
Number of subjects: 86
Study 35641194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 35641481 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg (day 1), Apatinib 250 mg daily, Eribulin 1.4 mg/m²
Number of subjects: 46
Study 35641780 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg) with milvexian (30 mg)
Number of subjects: 28
Study 35641780 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg) with milvexian (30 mg)
Number of subjects: 28
Study 35641830 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable percutaneous interspinous process spacer (IPS) (LobsterProject® Techlamed®)
Number of subjects: 59
Study 35641923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand and Move at Work intervention
Number of subjects: 12
Study 35641962 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1 deficiency
Number of subjects: 489
Study 35641962 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG2 deficiency
Number of subjects: 489
Study 35641962 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG3 deficiency
Number of subjects: 489
Study 35641962 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG4 deficiency
Number of subjects: 489
Study 35641962 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or more IgG subclass deficiencies
Number of subjects: 489
Study 35642431 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-011 (calicheamicin-based antibody-drug conjugate)
Number of subjects: 0
Study 35642432 — intervention group
Group type: EXPERIMENTAL
Intervention: H3B-6545, a covalent ERα antagonist
Number of subjects: 0
Study 35642432 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant (standard-of-care)
Number of subjects: 0
Study 35642907 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study 35643089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (300 mg orally once a day from the 24th week of gestation until 6 weeks postpartum)
Number of subjects: 1194
Study 35643089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate for more than 4 weeks before giving birth
Number of subjects: 1194
Study 35643089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate for less than 4 weeks before giving birth
Number of subjects: 1194
Study 35643089 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate ineligible group
Number of subjects: 1194
Study 35643089 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate ineligible group without HBIg
Number of subjects: 1194
Study 35643306 — intervention group
Group type: COMPARATOR
Intervention: TRAIL levels in COVID-19 patients
Number of subjects: 132
Study 35643306 — intervention group
Group type: COMPARATOR
Intervention: IP-10 levels in COVID-19 patients
Number of subjects: 132
Study 35643306 — intervention group
Group type: COMPARATOR
Intervention: CRP levels in COVID-19 patients
Number of subjects: 132
Study 35643306 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity as a predictor of in-ICU mortality
Number of subjects: 132
Study 35643306 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP as a predictor of in-ICU mortality
Number of subjects: 132
Study 35643306 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IP-10 as a predictor of in-ICU mortality
Number of subjects: 132
Study 35643387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rod intercept time (RIT)
Number of subjects: 191
Study 35643387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone decay, cone plateau, time to rod-cone break, rod adaptation rate (S2), area under the curve
Number of subjects: 191
Study 35643387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone plateau
Number of subjects: 191
Study 35643571 — intervention group
Group type: COMPARATOR
Intervention: Mean 24-h systolic BP in T2D (128.8±11.7 mmHg)
Number of subjects: 205
Study 35643571 — intervention group
Group type: COMPARATOR
Intervention: Concentric LV remodeling in T2D (mass/volume 0.91±0.15 g/mL)
Number of subjects: 205
Study 35643571 — intervention group
Group type: COMPARATOR
Intervention: Decreased myocardial perfusion reserve in T2D (2.82±0.83)
Number of subjects: 205
Study 35643571 — intervention group
Group type: COMPARATOR
Intervention: Systolic dysfunction in T2D (global longitudinal strain 16.0±2.3%)
Number of subjects: 205
Study 35643571 — intervention group
Group type: COMPARATOR
Intervention: Diastolic dysfunction in T2D (E/e' 9.30±2.43)
Number of subjects: 205
Study 35643571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 24-h systolic BP
Number of subjects: 205
Study 35643571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 24-h diastolic BP
Number of subjects: 205
Study 35643589 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMPEG 0.006 mg/kg plus nivolumab 360 mg intravenously every 3 weeks
Number of subjects: 41
Study 35643624 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 125 mg/d
Number of subjects: 813
Study 35643624 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI) initiated at 75/100 mg/d
Number of subjects: 813
Study 35643624 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (PAL+AI)
Number of subjects: 813
Study 35643966 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 76
Study 35643967 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-µg bimatoprost implant
Number of subjects: 395
Study 35643967 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol maleate 0.5%
Number of subjects: 395
Study 35644866 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with diabetes in the iNPHORM study
Number of subjects: 1206
Study 35644866 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors identified in the final model
Number of subjects: 1206
Study 35646453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 35646453 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study 35646641 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal prophylaxis with methotrexate
Number of subjects: 29
Study 35646641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate-based treatment
Number of subjects: 29
Study 35646641 — intervention group
Group type: COMPARATOR
Intervention: PTCL without initial CNS disease
Number of subjects: 29
Study 35646641 — intervention group
Group type: COMPARATOR
Intervention: PTCL with initial CNS and systemic disease
Number of subjects: 29
Study 35646641 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS relapse
Number of subjects: 29
Study 35646767 — intervention group
Group type: EXPERIMENTAL
Intervention: Baropodometric assessment before and after a 5-month clinical training session
Number of subjects: 194
Study 35647043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 35647043 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35647050 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion over lung meridian (LU5)
Number of subjects: 80
Study 35647050 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion over heart meridian (HT3)
Number of subjects: 80
Study 35647062 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Multi-Point Pacing (3P-MPP)
Number of subjects: 0
Study 35647062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Multi-Point Pacing
Number of subjects: 0
Study 35647063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-RSS <50%
Number of subjects: 1506
Study 35647063 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi-RSS <50%
Number of subjects: 1506
Study 35647063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial-RSS <50%
Number of subjects: 1506
Study 35647078 — intervention group
Group type: EXPERIMENTAL
Intervention: LSTM_INR model
Number of subjects: 782
Study 35647078 — intervention group
Group type: COMPARATOR
Intervention: MAPB_INR model
Number of subjects: 782
Study 35647344 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite blocks
Number of subjects: 54
Study 35647344 — intervention group
Group type: COMPARATOR
Intervention: Ceramic blocks
Number of subjects: 54
Study 35647711 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron (PF-06882961), an orally bioavailable small-molecule GLP-1R agonist, administered orally.
Number of subjects: 0
Study 35647759 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35647908 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab 200 mg every 3 weeks (21 patients), 1 mg/kg every 2 weeks (2 patients), 3 mg/kg every 2 weeks (1 patient)
Number of subjects: 24
Study 35647908 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 24
Study 35647938 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 70
Study 35647938 — intervention group
Group type: EXPERIMENTAL
Intervention: G/nab-P
Number of subjects: 70
Study 35647938 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective regimen as predicted by the chemosensitivity assay
Number of subjects: 70
Study 35647938 — intervention group
Group type: COMPARATOR
Intervention: Entire study cohort
Number of subjects: 70
Study 35648149 — intervention group
Group type: EXPERIMENTAL
Intervention: 4β-hydroxycholesterol (4βOHC) concentrations
Number of subjects: 96
Study 35648151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 2814
Study 35648151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 2814